Report

The global point-of-care (POC) diagnostic market was valued at USD 15.05 Billion in 2024, driven by the increasing demand to produce therapeutic drugs across the globe. The market is anticipated to grow at a CAGR of 8.50% during the forecast period of 2025-2034 to achieve a value of USD 34.03 Billion by 2034.

Point-of-Care (POC) Diagnostic Market Overview

Point-of-care (POC) diagnostics refer to medical testing conducted near the patient, enabling immediate results and quicker decision-making. These tests are designed to be portable, user-friendly, and efficient, often requiring minimal training to operate. POC diagnostics are commonly used in settings such as clinics, homes, ambulances, or remote areas, eliminating the need to send samples to centralised laboratories. They are vital for rapid detection of conditions like infections, diabetes, or heart diseases, facilitating timely treatment and improving patient outcomes. Examples include glucometers, rapid antigen tests, and blood gas analysers.

Point-of-Care (POC) Diagnostic Market Growth Drivers

Strategic Acquisitions to Enhance Point-of-Care Diagnostic Capabilities

The increasing demand for rapid diagnostics, driven by the need for immediate healthcare decision-making and decentralised patient care, is boosting the growth of the market. For instance, in January �2025, bioMerieux, a leader in in vitro diagnostics, acquired SpinChip Diagnostics ASA, a Norwegian company specialising in immunoassay platforms for near-patient testing. This acquisition includes a small benchtop analyser capable of delivering results from a whole blood sample within 10 minutes, maintaining laboratory-level sensitivity. The integration of SpinChip's innovative platform is expected to accelerate bioMerieux's POC capabilities, fostering faster, high-quality diagnostic testing in decentralised healthcare settings, thereby expanding market opportunities in the forecast period.

Expansion of Multi-Assay Platforms to Accelerate Point-of-Care (POC) Diagnostic Market Demand

The growing need for integrated diagnostic platforms that provide quick, accurate results at the point of care is shaping the market. For instance, in July �2024, Roche completed the acquisition of LumiraDx's POC technology, which includes a multi-assay platform capable of performing a wide range of immunoassay and clinical chemistry tests. The platform's potential for expansion into molecular testing further strengthens Roche's portfolio. This acquisition allows Roche to enhance its decentralised diagnostic offerings, broadening access to timely and actionable results for both patients and healthcare providers. The integration of LumiraDx's technology is expected to boost global market growth, driving wider adoption of POC diagnostic solutions.

Point-of-Care (POC) Diagnostic Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Growing Demand for Rapid Diagnostics Accelerating Market Growth

The increasing emphasis on reducing diagnostic turnaround times is driving the adoption of point-of-care diagnostic solutions. These devices enable healthcare providers to make immediate clinical decisions, improving patient outcomes. In emergency settings, rapid diagnostics are indispensable for critical conditions like sepsis, heart attacks, and infectious diseases. The global shift towards decentralised healthcare models is also enhancing the demand for faster diagnostic tools. Additionally, advancements in testing methods, such as molecular diagnostics and immunoassays, ensure high sensitivity and specificity in shorter durations, further boosting market adoption. This trend is expected to continue shaping the growth trajectory of the POC diagnostic industry.

Focus on Personalised Medicine to Enhance Point-of-Care (POC) Diagnostic Market Value

The rise of personalised medicine is a significant trend shaping the market. Tailored diagnostic solutions are increasingly sought for managing chronic diseases, ensuring treatments align with individual patient needs. Point-of-care devices are being developed to support genetic and biomarker testing, enabling precise diagnosis and treatment strategies. This focus on personalisation is particularly prominent in oncology, cardiology, and rare disease management. As healthcare shifts towards patient-centric models, the demand for POC solutions that facilitate personalised care is expected to grow. This trend is driving innovation, ensuring the continued evolution of diagnostic tools tailored to unique patient profiles.

Growing Role of Home-Based Testing to Augment Point-of-Care (POC) Diagnostic Market Size

The market is witnessing significant growth due to the rising popularity of home-based testing. Consumers increasingly prefer diagnostic tools that offer convenience, privacy, and ease of use. Home-based POC devices, such as blood glucose monitors, ovulation kits, and at-home COVID-19 tests, exemplify this trend. The shift towards preventive healthcare and early diagnosis further supports the adoption of these devices. Moreover, telemedicine advancements integrate seamlessly with home-based diagnostics, enabling remote consultations and monitoring. As the demand for accessible healthcare rises, home-based POC solutions are expected to contribute significantly to the overall market value.

Integration of Wearable Technology to Drive Point-of-Care (POC) Diagnostic Market Growth

The integration of wearable technology with point-of-care diagnostics is emerging as a transformative trend in the global market. Wearable devices equipped with biosensors can continuously monitor health parameters like glucose levels, heart rate, and oxygen saturation, providing real-time insights. These innovations cater to the growing demand for proactive health management and preventive care. Additionally, advancements in data connectivity enable seamless sharing of diagnostic information with healthcare providers for better clinical decision-making. As wearable diagnostics gain acceptance among consumers for convenience and reliability, this trend is expected to create significant growth opportunities in the market.

Point-of-Care (POC) Diagnostic Market Segmentation

Point-of-Care (POC) Diagnostic Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Product

- Glucose Monitoring Kits
- Infectious Diseases Testing Kits
- Pregnancy and Fertility Testing Kits
- Haematology Testing Kits
- Cardiometabolic Monitoring Kits
- Urinalysis Testing Devices
- Coagulation Monitoring Kits
- Tumour or Cancer Markers Testing Devices
- Cholesterol Testing Strips
- Drugs of Abuse Testing Kits
- Faecal Occult Testing Kits
- Others

Market Breakup by Platform

- Lateral Flow Assays
- Dipsticks
- Microfluidics
- Molecular Diagnostics
- Immunoassays
- Others

Market Breakup by Mode of Purchase

- Prescription-Based Products
- OTC Products

Market Breakup by End User

- Professional Diagnostic Centres
- Hospitals/Critical Care Centres
- Assisted Living Healthcare Facilities
- Research Laboratories

Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

Point-of-Care (POC) Diagnostic Market Share

Glucose Monitoring Kits to Lead the Segment by Treatment Type

Glucose monitoring kits will likely hold the largest market share due to the rising prevalence of diabetes and increased focus on diabetes management. These kits provide real-time glucose level tracking, essential for improving patient outcomes and reducing complications. The growing adoption of home-based care and portable devices drives their widespread use. As per the analysis �by Expert Market Research, the global glucose monitoring devices market is anticipated to grow at a CAGR of 11.3% during the forecast period of 2025-2034. Moreover, continuous innovations, such as integration with smartphone apps and wearable technologies, enhance usability and data tracking. With diabetes cases projected to increase globally, this segment is poised for sustained growth, contributing significantly to the overall expansion of the point-of-care diagnostic market.

Infectious Diseases Testing Kits to Lead the Point-of-Care (POC) Diagnostic Market Segmentation by Indication Type

Infectious disease testing kits are expected to dominate the market by indication type due to increasing demand for rapid and accurate diagnostic tools during outbreaks like COVID-19. These kits enable immediate identification of pathogens, improving disease control and treatment efficacy. Their importance is amplified in resource-limited settings, where timely diagnosis is crucial. Technological advancements, including molecular diagnostics and multiplex testing, have further boosted their efficiency and adoption. Government initiatives and global health programmes targeting infectious disease management continue to drive growth.

Hospitals/Critical Care Centres to Hold Significant Point-of-Care (POC) Diagnostic Market Value for End User Segmentation

Hospitals and critical care centres represent a notable market share among end users due to their high diagnostic testing volumes and advanced infrastructure. These facilities rely on POC diagnostics for emergency, inpatient, and critical care settings, where rapid results significantly influence clinical decisions. The integration of point-of-care devices into hospital workflows enhances efficiency, particularly in managing chronic diseases and acute conditions. Increasing investments in healthcare infrastructure and the adoption of sophisticated diagnostic technologies further fuel this segment's growth. As demand for advanced healthcare services rises globally, hospitals and critical care centres will continue driving the POC diagnostic market forward.

Point-of-Care (POC) Diagnostic Market Analysis by Region

North America is expected to hold the largest share of the market, driven by advanced healthcare infrastructure, high adoption of innovative technologies, and robust investments in research and development. The prevalence of chronic diseases like diabetes and cardiovascular conditions further boosts demand for point-of-care testing. Additionally, the region's supportive regulatory environment facilitates the swift approval of diagnostic devices, while strong reimbursement frameworks enhance accessibility.

Europe is another prominent region, owing to its growing focus on decentralised healthcare and home-based diagnostics. Increased government funding for infectious disease management and early diagnosis, coupled with the rising geriatric population, drives market expansion. The integration of AI in diagnostics and the region's strong emphasis on preventive healthcare also contribute significantly to growth.

Leading Players in the Point-of-Care (POC) Diagnostic Market

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Abbott Point of Care Inc.

Headquartered in Princeton, New Jersey, Abbott Point of Care was established in 1888 and specialises in innovative diagnostic solutions. The company's flagship platform, i-STAT, provides portable and rapid testing across various healthcare settings, including hospitals and ambulances. Their portfolio includes diagnostic tools for critical care parameters such as blood gases, electrolytes, and cardiac markers. Abbott's commitment to improving patient outcomes through decentralised and accurate diagnostics has positioned it as a leader in the global Point-of-Care market, catering to diverse medical needs with advanced, user-friendly technologies.

F. Hoffmann-La Roche Ltd

Founded in 1896 and headquartered in Basel, Switzerland, F. Hoffmann-La Roche Ltd is a global leader in diagnostics and pharmaceuticals. The company's diagnostics portfolio focuses on POC solutions for diseases like diabetes, infectious diseases, and oncology. Roche's cobas and Accu-Chek platforms exemplify its commitment to delivering innovative, precise, and accessible diagnostic tools. With a strong emphasis on personalised healthcare and advanced technologies, Roche continues to shape the global diagnostic market, ensuring patients receive timely and effective care across clinical and home-based settings.

Chembio Diagnostics, Inc.

Chembio Diagnostics, Inc., headquartered in Medford, New York, was established in 1985 and specialises in rapid diagnostic tests. Its portfolio includes point-of-care solutions for infectious diseases such as HIV, syphilis, and COVID-19, featuring advanced technologies like the Dual Path Platform (DPP). Chembio's diagnostics are widely used in resource-limited settings, addressing global healthcare challenges with cost-effective and reliable tools. The company's focus on innovation and partnerships has strengthened its market presence, contributing to improved healthcare access and timely disease management worldwide.

Johnson & Johnson Services, Inc.

Headquartered in New Brunswick, New Jersey, and founded in 1886, Johnson & Johnson Services is a diversified healthcare leader. Its diagnostics division offers POC solutions under the brand Veridex, catering to oncology and other medical fields. Known for its innovation, the company integrates advanced technologies with user-centric designs to address evolving healthcare needs. Johnson & Johnson's commitment to improving health outcomes through accessible, accurate, and rapid diagnostics aligns with its broader mission to advance global healthcare standards and patient care.

Other key players in the market include Siemens AG, Danaher Corp as well as Becton, Dickinson and Company.

Key Questions Answered in the Point-of-Care (POC) Diagnostic Market

- What was the global point-of-care (POC) diagnostic market value in 2024?
- What is the point-of-care (POC) diagnostic market forecast outlook for 2025-2034?
- What is market segmentation based on product?
- How is the market segmented based on platform?
- How is the market segmented based on modes of purchase?
- How is the market segmented based on the end users?
- What are the major factors aiding the point-of-care (POC) diagnostic market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major point-of-care (POC) diagnostic market trends?
- Which product will lead the market segment?
- Which platforms will lead the market segment?
- Which mode of purchase will lead the market segment?
- Which end user will lead the market segment?
- Who are the key players involved in the point-of-care (POC) diagnostic market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?